
Donna Senger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8331582/publications.pdf Version: 2024-02-01



DONNA SENCED

#	Article	IF	CITATIONS
1	Eukaryotic initiation factor 5B (eIF5B) regulates temozolomide-mediated apoptosis in brain tumour stem cells (BTSCs). Biochemistry and Cell Biology, 2020, 98, 647-652.	2.0	4
2	Development of a peptide-based delivery platform for targeting malignant brain tumors. Biomaterials, 2020, 252, 120105.	11.4	15
3	Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 19098-19108.	7.1	42
4	Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma. Cancer Research, 2019, 79, 2111-2123.	0.9	28
5	ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts. PLoS ONE, 2018, 13, e0202860.	2.5	28
6	Renal immune surveillance and dipeptidase-1 contribute to contrast-induced acute kidney injury. Journal of Clinical Investigation, 2018, 128, 2894-2913.	8.2	74
7	Activation of NOTCH Signaling by Tenascin-C Promotes Growth of Human Brain Tumor-Initiating Cells. Cancer Research, 2017, 77, 3231-3243.	0.9	61
8	The Role of Neurotrophin Signaling in Gliomagenesis. Vitamins and Hormones, 2017, 104, 367-404.	1.7	11
9	Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells. Oncotarget, 2016, 7, 59360-59376.	1.8	34
10	Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma. Clinical Cancer Research, 2016, 22, 3860-3875.	7.0	142
11	Glioma invasion mediated by the p75 neurotrophin receptor (p75NTR/CD271) requires regulated interaction with PDLIM1. Oncogene, 2016, 35, 1411-1422.	5.9	47
12	TMIC-02CELL AUTONOMOUS AND CELL NON-AUTONOMOUS ROLES OF p75 NEUROTROPHIN RECEPTOR (p75NTR) IN GLIOMA INVASION. Neuro-Oncology, 2015, 17, v214.6-v214.	1.2	0
13	ADAM-9 is a novel mediator of tenascin-C-stimulated invasiveness of brain tumor–initiating cells. Neuro-Oncology, 2015, 17, 1095-1105.	1.2	59
14	Novel <i>MSH6</i> Mutations in Treatment-NaÃ ⁻ ve Glioblastoma and Anaplastic Oligodendroglioma Contribute to Temozolomide Resistance Independently of <i>MGMT</i> Promoter Methylation. Clinical Cancer Research, 2014, 20, 4894-4903.	7.0	51
15	Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin. Neuro-Oncology, 2013, 15, 904-920.	1.2	44
16	Efficacy and Safety/Toxicity Study of Recombinant Vaccinia Virus JX-594 in Two Immunocompetent Animal Models of Glioma. Molecular Therapy, 2010, 18, 1927-1936.	8.2	83
17	Myxoma Virus Virotherapy for Glioma in Immunocompetent Animal Models: Optimizing Administration Routes and Synergy with Rapamycin. Cancer Research, 2010, 70, 598-608.	0.9	90
18	Proliferation of Human Glioblastoma Stem Cells Occurs Independently of Exogenous Mitogens. Stem Cells, 2009, 27, 1722-1733.	3.2	175

DONNA SENGER

#	Article	IF	CITATIONS
19	Efficacy of Systemically Administered Oncolytic Vaccinia Virotherapy for Malignant Gliomas Is Enhanced by Combination Therapy with Rapamycin or Cyclophosphamide. Clinical Cancer Research, 2009, 15, 2777-2788.	7.0	142
20	Oncolytic Efficacy of Recombinant Vesicular Stomatitis Virus and Myxoma Virus in Experimental Models of Rhabdoid Tumors. Clinical Cancer Research, 2008, 14, 1218-1227.	7.0	47
21	Population-based Study of Medulloblastoma: Outcomes in Alberta from 1975 to 1996. Canadian Journal of Neurological Sciences, 2008, 35, 210-215.	0.5	11
22	Gamma-Secretase Represents a Therapeutic Target for the Treatment of Invasive Glioma Mediated by the p75 Neurotrophin Receptor. PLoS Biology, 2008, 6, e289.	5.6	66
23	The p75 Neurotrophin Receptor Is a Central Regulator of Glioma Invasion. PLoS Biology, 2007, 5, e212.	5.6	150
24	Proteolytic Disassembly Is a Critical Determinant for Reovirus Oncolysis. Molecular Therapy, 2007, 15, 1512-1521.	8.2	76
25	Targeting Human Medulloblastoma: Oncolytic Virotherapy with Myxoma Virus Is Enhanced by Rapamycin. Cancer Research, 2007, 67, 8818-8827.	0.9	97
26	Effects of Intravenously Administered Recombinant Vesicular Stomatitis Virus (VSV ΔM51) on Multifocal and Invasive Gliomas. Journal of the National Cancer Institute, 2006, 98, 1546-1557.	6.3	88
27	Myxoma Virus Is a Novel Oncolytic Virus with Significant Antitumor Activity against Experimental Human Gliomas. Cancer Research, 2005, 65, 9982-9990.	0.9	149
28	Efficacy and Safety Evaluation of Human Reovirus Type 3 in Immunocompetent Animals. Clinical Cancer Research, 2004, 10, 8561-8576.	7.0	78
29	Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer. Gene Therapy, 2004, 11, 1579-1589.	4.5	45
30	Spatial requirements for TrkA kinase activity in the support of neuronal survival and axon growth in rat sympathetic neurons. Neuropharmacology, 2003, 45, 995-1010.	4.1	33
31	Long-Term Survivors of Glioblastoma. Cancer Journal (Sudbury, Mass), 2003, 9, 214-221.	2.0	51
32	Reovirus as an Oncolytic Agent Against Experimental Human Malignant Gliomas. Journal of the National Cancer Institute, 2001, 93, 903-912.	6.3	203
33	Rapid Retrograde Tyrosine Phosphorylation of trkA and Other Proteins in Rat Sympathetic Neurons in Compartmented Cultures. Journal of Cell Biology, 1997, 138, 411-421.	5.2	153
34	Spatial Regulation of Neuronal Gene Expression in Response to Nerve Growth Factor. Developmental Biology, 1997, 184, 1-9.	2.0	31
35	Delivery of newly synthesized tubulin to rapidly growing distal axons of sympathetic neurons in compartmented cultures Journal of Cell Biology, 1996, 135, 701-709.	5.2	43
36	Evidence that Protein Kinase C Activities Involved in Regulating Neurite Growth Are Localized to Distal Neurites. Journal of Neurochemistry, 1994, 63, 868-878.	3.9	47